- Home
- PRTA vs PFLT Comparison
PRTA vs PFLT Comparison
Compare PRTA & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- PFLT
- Stock Information
- Founded
- PRTA 2012
- PFLT 2010
- Country
- PRTA Ireland
- PFLT United States
- Employees
- PRTA N/A
- PFLT N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- PRTA Health Care
- PFLT Finance
- Exchange
- PRTA Nasdaq
- PFLT Nasdaq
- Market Cap
- PRTA 809.8M
- PFLT 789.0M
- IPO Year
- PRTA N/A
- PFLT N/A
- Fundamental
- Price
- PRTA $9.20
- PFLT $9.71
- Analyst Decision
- PRTA Buy
- PFLT Buy
- Analyst Count
- PRTA 9
- PFLT 4
- Target Price
- PRTA $54.57
- PFLT $11.38
- AVG Volume (30 Days)
- PRTA 572.3K
- PFLT 1.9M
- Earning Date
- PRTA 05-07-2025
- PFLT 05-12-2025
- Dividend Yield
- PRTA N/A
- PFLT 12.65%
- EPS Growth
- PRTA N/A
- PFLT 16.92
- EPS
- PRTA N/A
- PFLT 1.37
- Revenue
- PRTA $135,157,000.00
- PFLT $215,391,000.00
- Revenue This Year
- PRTA N/A
- PFLT $48.14
- Revenue Next Year
- PRTA $131.71
- PFLT $9.03
- P/E Ratio
- PRTA N/A
- PFLT $7.10
- Revenue Growth
- PRTA 47.92
- PFLT 47.56
- 52 Week Low
- PRTA $9.10
- PFLT $8.82
- 52 Week High
- PRTA $25.42
- PFLT $12.02
- Technical
- Relative Strength Index (RSI)
- PRTA 26.58
- PFLT 36.56
- Support Level
- PRTA $9.30
- PFLT $9.25
- Resistance Level
- PRTA $10.45
- PFLT $9.78
- Average True Range (ATR)
- PRTA 0.81
- PFLT 0.43
- MACD
- PRTA -0.15
- PFLT -0.07
- Stochastic Oscillator
- PRTA 2.77
- PFLT 36.33
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.